- Fool.co.uk•16 hours ago
Bilaal Mohamed reveals two perfect picks for long-term income investors.
- Zacks•21 hours ago
Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.
- Benzinga•3 days ago
Following AstraZeneca plc (ADR) (NYSE: AZN )’s strong start to 2017, including a positive data report for breast cancer treatment Lynparza, investors await a barrage of news highlighting significant findings ...
AZN.L: Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed price. Currency in GBp
Add to watchlist
|Bid||4,560.00 x 6100|
|Ask||4,630.00 x 13000|
|Day's range||4,568.50 - 4,675.17|
|52-week range||3,680.00 - 5,505.00|
|PE ratio (TTM)||16.70|
|Dividend & yield||2.80 (4.97%)|
|1y target est||N/A|